BR112018075281A2 - Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer - Google Patents

Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer Download PDF

Info

Publication number
BR112018075281A2
BR112018075281A2 BR112018075281-9A BR112018075281A BR112018075281A2 BR 112018075281 A2 BR112018075281 A2 BR 112018075281A2 BR 112018075281 A BR112018075281 A BR 112018075281A BR 112018075281 A2 BR112018075281 A2 BR 112018075281A2
Authority
BR
Brazil
Prior art keywords
sequence
fact
virus
protein
peptide
Prior art date
Application number
BR112018075281-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Luo Tianci
Molina Rene
CASTILLE Gabriel
Original Assignee
Wellstat Immuno Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Immuno Therapeutics, Llc filed Critical Wellstat Immuno Therapeutics, Llc
Publication of BR112018075281A2 publication Critical patent/BR112018075281A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018075281-9A 2017-05-10 2018-05-10 Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer BR112018075281A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504120P 2017-05-10 2017-05-10
US62/504,120 2017-05-10
PCT/US2018/032018 WO2018209052A1 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112018075281A2 true BR112018075281A2 (pt) 2020-02-11

Family

ID=64105722

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075281-9A BR112018075281A2 (pt) 2017-05-10 2018-05-10 Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer

Country Status (12)

Country Link
US (2) US11274141B2 (enExample)
EP (1) EP3621635A4 (enExample)
JP (1) JP7161940B2 (enExample)
KR (3) KR20250118857A (enExample)
CN (1) CN109414483B (enExample)
AU (1) AU2018265258B2 (enExample)
BR (1) BR112018075281A2 (enExample)
CA (1) CA3026892A1 (enExample)
IL (1) IL263979B2 (enExample)
MX (1) MX2018015599A (enExample)
WO (1) WO2018209052A1 (enExample)
ZA (1) ZA201808040B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN112759654A (zh) * 2019-11-06 2021-05-07 深圳普菲科生命科技有限公司 一种病毒囊膜蛋白装配系统及其方法和应用
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
AU2022227480A1 (en) * 2021-02-26 2023-09-14 Sillajen, Inc. Oncolytic virus and use thereof
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
KR20240003051A (ko) * 2022-06-29 2024-01-08 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
AU2023338427A1 (en) * 2022-09-07 2025-04-03 Sillajen, Inc. Novel use of oncolytic virus

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
PT1486211E (pt) 1993-04-30 2009-02-02 Wellstat Biologics Corp Composições para tratamento do cancro utilizando vírus
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
EP1030928A1 (en) 1997-11-21 2000-08-30 Gesellschaft für biotechnologische Forschung mbH (GBF) Development of viruses resistant to inactivation by the human complement system
AP1968A (en) 1997-12-22 2009-04-30 Univ Tennessee Res Corp Recombinant rhabdovirus containing a heterologous fusion protein.
EP1071705A2 (en) * 1998-04-02 2001-01-31 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
AU4246900A (en) 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP2292259A3 (en) * 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
EP1784506B1 (en) 2004-07-21 2010-08-25 Dana-Farber Cancer Institute, Inc. Lentiviral vectors and uses thereof
JP5050198B2 (ja) 2006-09-05 2012-10-17 国立大学法人大阪大学 ヒト補体制御因子発現遺伝子およびその利用
WO2008118258A2 (en) * 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
KR20090122465A (ko) * 2007-03-01 2009-11-30 어드벤스드 비젼 테라피스, 인코포레이티드 염증성 질환의 치료
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
JP2014516517A (ja) 2011-04-29 2014-07-17 キージーン・エン・フェー グリホサート耐性強化
CA2833931C (en) 2011-05-05 2021-05-04 Wellstat Immunotherapeutics, Llc Complement factor b analogs and their uses
CN110078831A (zh) * 2011-12-01 2019-08-02 圆祥生命科技股份有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
FI3888674T3 (fi) * 2014-04-07 2024-07-02 Novartis Ag Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
RS61907B1 (sr) * 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
EP3458576A4 (en) 2016-05-19 2020-03-25 Turnstone Limited Partnership PSEUDOTYPIZED ONCOLYTIC RHABDOVIRUS AND THEIR USE IN COMBINATION THERAPY

Also Published As

Publication number Publication date
US20220169701A1 (en) 2022-06-02
RU2018146446A (ru) 2021-06-10
AU2018265258A1 (en) 2019-01-17
KR102839445B1 (ko) 2025-07-28
IL263979B1 (en) 2023-05-01
IL263979A (en) 2019-02-28
IL263979B2 (en) 2023-09-01
KR20250118857A (ko) 2025-08-06
KR102662049B1 (ko) 2024-05-23
JP7161940B2 (ja) 2022-10-27
ZA201808040B (en) 2019-09-25
US20190194292A1 (en) 2019-06-27
EP3621635A1 (en) 2020-03-18
CA3026892A1 (en) 2018-11-15
EP3621635A4 (en) 2021-02-24
RU2018146446A3 (enExample) 2021-09-10
US11274141B2 (en) 2022-03-15
MX2018015599A (es) 2019-05-16
KR20200005721A (ko) 2020-01-16
CN109414483B (zh) 2025-10-24
AU2018265258B2 (en) 2023-01-05
KR20240073085A (ko) 2024-05-24
WO2018209052A1 (en) 2018-11-15
CN109414483A (zh) 2019-03-01
JP2020519230A (ja) 2020-07-02

Similar Documents

Publication Publication Date Title
BR112018075281A2 (pt) Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer
ES2231494T3 (es) Compuestos antiinflamatorios y sus usos.
ES2281341T3 (es) Lectina humana recombinante que se une a manano.
CN109475613A (zh) 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达
Xu et al. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment
Richard-Fiardo et al. Evaluation of tetrafunctional block copolymers as synthetic vectors for lung gene transfer
US20070173443A1 (en) C-Terminal P53 Palindromic Peptide That Induces Apoptosis Of Cells With Aberrant P53 And Uses Thereof
US9808505B2 (en) Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)
US20240083966A1 (en) Vesicular stomatitis viruses
US20140271564A1 (en) Vesicular stomatitis viruses containing a maraba virus glycoprotein polypeptide
CA3009883C (en) A combination therapy using reic/dkk-3 gene and a checkpoint inhibitor
US7052692B1 (en) Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
US20250064873A1 (en) TNFSF-L Fusion Proteins and Uses Thereof
BR112019015569A2 (pt) Proteínas de fusão do fator ix e métodos para a sua produção e uso
ES2390763T3 (es) Fragmentos peptídicos del factor HARP que inhiben la angiogénesis
ES2751361T3 (es) Factor VIII de la coagulación con inmunogenicidad reducida
US20220251167A1 (en) T-Cell Receptor for Treating Fibrolamellar Hepatocellular Carcinoma
KR20240021898A (ko) 돌연변이된 아넥신 a5 폴리펩타이드 및 치료 목적을 위한 이의 용도
NZ748798A (en) Enveloped virus resistant to complement inactivation for the treatment of cancer
US20010036929A1 (en) Xrcc3 is required for assembly of Rad51-complexes in vivo
WO2025212872A1 (en) T-bet induces tumor cell apoptosis and its utility in cancer therapy
CN119744267A (zh) 一种抑制肿瘤进展并延长荷瘤个体生存期的复制型溶瘤腺病毒及其应用
Meliani et al. 595. Enhanced Liver Transduction and Efficient Protection from Pre-Existing Neutralizing Antibodies with Exosome-Associated AAV8 Vectors
Trueb et al. Adenovirus‐mediated blockade of lymphotoxin‐β inhibits the induction of contact sensitivity in mice
CN116782917A (zh) 用于全身递送的溶瘤病毒及增强的抗肿瘤活性

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: PHARMA CINQ, LLC (US)